Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Prázný, M."" wg kryterium: Wszystkie pola

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 362
Tytuł:
Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
Autorzy:
Schernthaner G
Khunti K
Lotan C
Burnier M
Drexel H
Prázný M
Pokaż więcej
Temat:
Type-2 diabetes
Cardiovascular disease
CVOT
SGLT2 inhibitors
GLP-1 agonists
DPP4 inhibitors
Therapeutics. Pharmacology
RM1-950
Źródło:
Therapeutics and Clinical Risk Management, Vol Volume 13, Pp 1569-1576 (2017)
Opis pliku:
electronic resource
Relacje:
https://www.dovepress.com/relevance-of-positive-cardiovascular-outcome-trial-results-in-clinical-peer-reviewed-article-TCRM; https://doaj.org/toc/1178-203X
Dostęp URL:
https://doaj.org/article/c8db6db4ef114f999527692129d5cbcf  Link otwiera się w nowym oknie
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
Autorzy:
Schernthaner G
Jarvis S
Lotan C
Prázný M
Wanner C
Wascher TC
Pokaż więcej
Temat:
Type 2 diabetes
Cardiovascular risk
SGLT2 inhibitor
CVOTs
Empagliflozin
Therapeutics. Pharmacology
RM1-950
Źródło:
Therapeutics and Clinical Risk Management, Vol Volume 13, Pp 69-79 (2017)
Opis pliku:
electronic resource
Relacje:
https://www.dovepress.com/advances-in-the-management-of-cardiovascular-risk-for-patients-with-ty-peer-reviewed-article-TCRM; https://doaj.org/toc/1178-203X
Dostęp URL:
https://doaj.org/article/780d6965c5de457da43e280bebe96a26  Link otwiera się w nowym oknie
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Low Initial Adherence with Flash Glucose Monitoring is Not a Predictor of Long-Term Glycemic Outcomes: Longitudinal Analysis of the Association Between Experience, Adherence, and Glucose Control for FreeStyle Libre Users.
Autorzy:
Šoupal J; 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. .
Kao K; Abbott Diabetes Care, Alameda, CA, USA.
Brandner L; Abbott Diabetes Care, Alameda, CA, USA.
Grunberger G; Grunberger Diabetes Institute, Bloomfield Hills, MI, USA.; Department of Internal Medicine and Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA.
Prázný M; 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Pokaż więcej
Źródło:
Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2023 Jul; Vol. 14 (7), pp. 1231-1240. Date of Electronic Publication: 2023 May 22.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY study.
Autorzy:
Prázný M; 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. .
Suplotova L; Tyumen State Medical University, Tyumen, Russian Federation.
Gumprecht J; Department of Internal Medicine, Diabetology and Nephrology in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Kamenov Z; Department of Internal Medicine, Medical University Sofia, Sofia, Bulgaria.; Clinic of Endocrinology, University Hospital Alexandrovska, Sofia, Bulgaria.
Fülöp T; Department of Cardiology and Heart Surgery, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary.
Medvedchikov A; Boehringer Ingelheim RCV GmbH and Co. KG, Vienna, Austria.
Rosenzweig D; Boehringer Ingelheim RCV GmbH and Co. KG, Vienna, Austria.
Aleksandric M; Boehringer Ingelheim RCV GmbH and Co. KG, Vienna, Austria.
Pokaż więcej
Źródło:
Cardiovascular diabetology [Cardiovasc Diabetol] 2022 Oct 08; Vol. 21 (1), pp. 203. Date of Electronic Publication: 2022 Oct 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cardiovascular Diseases*/diagnosis
Cardiovascular Diseases*/epidemiology
Cardiovascular Diseases*/prevention & control
Diabetes Mellitus, Type 2*/diagnosis
Diabetes Mellitus, Type 2*/drug therapy
Diabetes Mellitus, Type 2*/epidemiology
Renal Insufficiency, Chronic*/diagnosis
Renal Insufficiency, Chronic*/drug therapy
Renal Insufficiency, Chronic*/epidemiology
Sodium-Glucose Transporter 2 Inhibitors*/adverse effects
Adult ; Benzhydryl Compounds ; Cross-Sectional Studies ; Glucagon-Like Peptide 1/therapeutic use ; Glucagon-Like Peptide-1 Receptor ; Glucosides ; Humans ; Hypoglycemic Agents/adverse effects ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.
Autorzy:
Guja C; Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. .
Giorgino F; Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
Blonde L; Department of Endocrinology, Ochsner Medical Center, Frank Riddick Diabetes Institute, New Orleans, LA, USA.
Ali A; Oakenhurst Medical Practice, Blackburn, UK.
Prázný M; 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
Meier JJ; Diabetes Division, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
Souhami E; Sanofi, Paris, France.
Lubwama R; Sanofi, Bridgewater, NJ, USA.
Ji C; Sanofi, Beijing, China.
Rosenstock J; Dallas Diabetes Research Center at Medical City, Dallas, TX, USA.
Pokaż więcej
Źródło:
Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2022 Jan; Vol. 13 (1), pp. 205-215. Date of Electronic Publication: 2021 Dec 11.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Hybrid Closed-Loop Systems for the Treatment of Type 1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe.
Autorzy:
Janez A; Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Zaloska 7, 1000, Ljubljana, Slovenia. .
Battelino T; University Medical Center Ljubljana, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Klupa T; Department of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland.; University Hospital, Kraków, Poland.
Kocsis G; Department of Medicine and Oncology, Semmelweis University Budapest, Budapest, Hungary.
Kuricová M; Pediatric Department, National Institute of Endocrinology and Diabetology, Ľubochňa, Slovakia.; Department of Children and Adolescents, Jessenius Faculty of Medicine, Comenius University Bratislava, Martin, Slovakia.
Lalić N; Faculty of Medicine of the University of Belgrade, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Belgrade, Serbia.
Stoian AP; Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Prázný M; Third Department of Internal Medicine, First Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czechia.
Rahelić D; Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia.; School of Medicine, University of Zagreb, Zagreb, Croatia.; School of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
Šoupal J; Third Department of Internal Medicine, First Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czechia.
Tankova T; Department of Endocrinology, Medical University of Sofia, Sofia, Bulgaria.
Zelinska N; Ukrainian Scientific and Practical Center of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine.
Pokaż więcej
Źródło:
Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2021 Dec; Vol. 12 (12), pp. 3107-3135. Date of Electronic Publication: 2021 Oct 25.
Typ publikacji:
Journal Article
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
Autorzy:
Czupryniak L; Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland. .
Dicker D; Department of Internal Medicine D, Hasharon Hospital, Rabin Medical Centre, Petah Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Lehmann R; Department of Endocrinology, Diabetes and Nutrition, University Hospital Zürich, Zürich, Switzerland.
Prázný M; 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic.
Schernthaner G; Department of Medicine I, Rudolfstiftung Hospital Vienna, 1030, Vienna, Austria. .; Medical University of Vienna, Vienna, Austria. .
Pokaż więcej
Źródło:
Cardiovascular diabetology [Cardiovasc Diabetol] 2021 Oct 01; Vol. 20 (1), pp. 198. Date of Electronic Publication: 2021 Oct 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Glycemic Control*
COVID-19/*complications
Diabetes Mellitus, Type 2/*complications
Diabetes Mellitus, Type 2/*drug therapy
Hypoglycemic Agents/*therapeutic use
Insulin/*therapeutic use
Humans ; Hypoglycemic Agents/adverse effects ; Practice Guidelines as Topic ; Risk Factors ; Time Factors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-World Study on Effectiveness of Insulin Glargine U300 After Oral Antidiabetic Drug Failure in Patients with Type 2 Diabetes in the Gulf Region.
Autorzy:
Khan, Niaz E. (AUTHOR)
Al Shaikh, AbdulRahman A. M. (AUTHOR)
Hassoun, Ahmed A. K. (AUTHOR)
Hassan, Amr M. (AUTHOR)
Salah, Mona M. (AUTHOR)
Al Abdella, Nabeela A. (AUTHOR)
Safarini, Saher S. M. (AUTHOR)
Al Dahi, Waleed A. (AUTHOR)
Akil, Yasser A. (AUTHOR)
Pokaż więcej
Źródło:
Diabetes Therapy. Mar2024, Vol. 15 Issue 3, p691-704. 14p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.
Autorzy:
Schernthaner G; Medical University of Vienna, Vienna, Austria. .
Karasik A; Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel. .
Abraitienė A; Clinic of Internal Diseases, Family Medicine and Oncology, Institute of Medicine, Faculty of Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania.
Ametov AS; Russian Medical Academy for Continuous Professional Education, Ministry of Education of the Russian Federation, Moscow, Russia.
Gaàl Z; Department of Medicine, András Jósa Teaching Hospital, Nyíregyháza, Hungary.
Gumprecht J; Medical University of Silesia, Katowice, Poland.
Janež A; Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre, Ljubljana, Slovenia.
Kaser S; Department of Internal Medicine I and CD Laboratory for Metabolic Crosstalk, Medical University of Innsbruck, Innsbruck, Tirol, Austria.
Lalić K; Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Mankovsky BN; National Medical Academy for Postgraduate Education, Kiev, Ukraine.
Moshkovich E; Diabetes and Endocrinology Clinic, Clalit Medical Services, Ramat Gan, Israel.
Past M; Estonian Diabetes Center, Tallinn, Estonia.
Prázný M; 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
Radulian G; Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Smirčić Duvnjak L; School of Medicine, University of Zagreb, Vuk Vrhovac University Clinic-UH Merkur, Zagreb, Croatia.
Tkáč I; Department of Internal Medicine 4, Faculty of Medicine, Safarik University in Košice, Košice, Slovakia.
Trušinskis K; Latvian Center of Cardiology, Stradiņš Clinical University Hospital, Rīga Stradiņš University, Riga, Latvia.
Pokaż więcej
Źródło:
Cardiovascular diabetology [Cardiovasc Diabetol] 2019 Aug 31; Vol. 18 (1), pp. 115. Date of Electronic Publication: 2019 Aug 31.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Evidence-Based Medicine*
Research Design*
Benzhydryl Compounds/*therapeutic use
Cardiovascular Diseases/*therapy
Clinical Trials as Topic/*methods
Diabetes Mellitus, Type 2/*drug therapy
Glucosides/*therapeutic use
Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
Benzhydryl Compounds/adverse effects ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/mortality ; Clinical Decision-Making ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/mortality ; Glucosides/adverse effects ; Hospitalization ; Humans ; Practice Guidelines as Topic ; Practice Patterns, Physicians' ; Protective Factors ; Risk Assessment ; Risk Factors ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 362

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies